Hadlima is the fourth biosimilar to Humira to gain FDA approval in the United States, following Hyrimoz (adalimumab-adaz, Sandoz) in 2018, Cyltezo (adalimumab-adbm, Boehringer Ingelheim) in 2017 and Amjevita (adalimumab-atto, Amgen) in 2016
Approved Biosimilars Humira USA Generic
Related Posts
Biosimilar Brands for Humira in Europe
There are many other Brands, but those brands are the...
بديل دواء هيوميرا في مصر Humira Egypt
بديل دواء هيوميرا في مصر Humira Biosimilars in Egypt Adalimumab...